Ocular Therapeutix, Inc. (OCUL)
Largest Insider Buys in Sector
OCUL Stock Price History Chart
OCUL Stock Performance
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing …
Insider Activity of Ocular Therapeutix, Inc.
Over the last 12 months, insiders at Ocular Therapeutix, Inc. have bought $12M and sold $778,212 worth of Ocular Therapeutix, Inc. stock.
On average, over the past 5 years, insiders at Ocular Therapeutix, Inc. have bought $6.24M and sold $524,432 worth of stock each year.
Highest buying activity among insiders over the last 12 months: SUMMER ROAD LLC (10 percent owner) — $12M.
The last purchase of 930,851 shares for transaction amount of $7M was made by SUMMER ROAD LLC (10 percent owner) on 2024‑02‑26.
List of Insider Buy and Sell Transactions, Ocular Therapeutix, Inc.
| 2024-08-23 | Sale | See Remarks | 20,880 0.0133% | $9.02 | $188,338 | +1.21% | ||
| 2024-08-23 | Sale | Chief Strategy Officer | 1,832 0.0012% | $9.02 | $16,525 | +1.21% | ||
| 2024-05-23 | Sale | See Remarks | 21,626 0.0139% | $5.79 | $125,215 | +48.62% | ||
| 2024-05-23 | Sale | Chief Strategy Officer | 2,274 0.0015% | $5.84 | $13,280 | +48.62% | ||
| 2024-02-26 | 10 percent owner | 930,851 0.6157% | $7.52 | $7M | -14.80% | |||
| 2024-02-05 | Sale | President and CEO | 19,642 0.0177% | $4.86 | $95,460 | +69.29% | ||
| 2024-02-05 | Sale | Chief Financial Officer | 6,212 0.0056% | $4.86 | $30,190 | +69.29% | ||
| 2024-02-05 | Sale | General Counsel | 6,029 0.0054% | $4.86 | $29,301 | +69.29% | ||
| 2024-02-05 | Sale | Chief Medical Officer | 6,346 0.0057% | $4.86 | $30,842 | +69.29% | ||
| 2024-02-05 | Sale | Chief Business Officer | 5,910 0.0053% | $4.86 | $28,723 | +69.29% | ||
| 2024-01-31 | Sale | President and CEO | 18,338 0.0168% | $4.95 | $90,773 | +72.02% | ||
| 2024-01-31 | Sale | Chief Financial Officer | 6,433 0.0059% | $4.95 | $31,843 | +72.02% | ||
| 2024-01-31 | Sale | General Counsel | 6,831 0.0063% | $4.95 | $33,813 | +72.02% | ||
| 2024-01-31 | Sale | Chief Medical Officer | 7,764 0.0071% | $4.95 | $38,432 | +72.02% | ||
| 2024-01-31 | Sale | Chief Business Officer | 5,147 0.0047% | $4.95 | $25,478 | +72.02% | ||
| 2023-12-14 | 10 percent owner | 1.54M 1.6722% | $3.25 | $5M | +110.84% | |||
| 2023-08-30 | President and CEO | 6,500 0.0082% | $3.81 | $24,765 | +30.39% | |||
| 2023-07-07 | Sale | Chief Medical Officer | 832 0.0011% | $4.93 | $4,102 | -7.77% | ||
| 2023-02-06 | Sale | President and CEO | 19,669 0.0255% | $4.24 | $83,397 | +6.12% | ||
| 2023-02-06 | Sale | Chief Financial Officer | 6,476 0.0084% | $4.24 | $27,458 | +6.12% |
Insider Historical Profitability
| SUMMER ROAD LLC | 10 percent owner | 8591401 5.4647% | $8.54 | 31 | 0 | +16.78% |
| Mattessich Antony C. | President and CEO | 588701 0.3745% | $8.54 | 6 | 3 | +1.23% |
| Notman Donald | Chief Financial Officer | 195356 0.1243% | $8.54 | 3 | 3 | +9.75% |
| Opaleye Management Inc. | 10 percent owner | 4918500 3.1285% | $8.54 | 2 | 0 | +99.18% |
| CHV II, L.P. | 10 percent owner | 2100138 1.3358% | $8.54 | 1 | 0 | +69.82% |
Institutional Investor Ownership
| Summer Road LLC | $130.68M | 9.27 | 14.36M | +87.46% | +$60.97M | 100 | |
| Vr Adviser Llc | $116.14M | 8.24 | 12.76M | +64.13% | +$45.38M | 5.64 | |
| Deep Track Capital Lp | $115.77M | 8.21 | 12.72M | +37.82% | +$31.77M | 0.53 | |
| BlackRock | $73.38M | 5.21 | 8.06M | +39.96% | +$20.95M | <0.01 | |
| The Vanguard Group | $65.84M | 4.67 | 7.24M | +41.36% | +$19.26M | <0.01 |